267 related articles for article (PubMed ID: 25638397)
1. Autophagy inhibition re-sensitizes pulse stimulation-selected paclitaxel-resistant triple negative breast cancer cells to chemotherapy-induced apoptosis.
Wen J; Yeo S; Wang C; Chen S; Sun S; Haas MA; Tu W; Jin F; Guan JL
Breast Cancer Res Treat; 2015 Feb; 149(3):619-29. PubMed ID: 25638397
[TBL] [Abstract][Full Text] [Related]
2. Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer.
Chittaranjan S; Bortnik S; Dragowska WH; Xu J; Abeysundara N; Leung A; Go NE; DeVorkin L; Weppler SA; Gelmon K; Yapp DT; Bally MB; Gorski SM
Clin Cancer Res; 2014 Jun; 20(12):3159-73. PubMed ID: 24721646
[TBL] [Abstract][Full Text] [Related]
3. Targeting of apoptotic pathways by SMAC or BH3 mimetics distinctly sensitizes paclitaxel-resistant triple negative breast cancer cells.
Panayotopoulou EG; Müller AK; Börries M; Busch H; Hu G; Lev S
Oncotarget; 2017 Jul; 8(28):45088-45104. PubMed ID: 28187446
[TBL] [Abstract][Full Text] [Related]
4. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
5. BAG3 Overexpression and Cytoprotective Autophagy Mediate Apoptosis Resistance in Chemoresistant Breast Cancer Cells.
Das CK; Linder B; Bonn F; Rothweiler F; Dikic I; Michaelis M; Cinatl J; Mandal M; Kögel D
Neoplasia; 2018 Mar; 20(3):263-279. PubMed ID: 29462756
[TBL] [Abstract][Full Text] [Related]
6. Enhanced autophagy reveals vulnerability of P-gp mediated epirubicin resistance in triple negative breast cancer cells.
Zhang LH; Yang AJ; Wang M; Liu W; Wang CY; Xie XF; Chen X; Dong JF; Li M
Apoptosis; 2016 Apr; 21(4):473-88. PubMed ID: 26767845
[TBL] [Abstract][Full Text] [Related]
7. TNFSF13 upregulation confers chemotherapeutic resistance via triggering autophagy initiation in triple-negative breast cancer.
Lin HY; Kuei CH; Lee HH; Lin CH; Chen YL; Chen CL; Lin YF
J Mol Med (Berl); 2020 Sep; 98(9):1255-1267. PubMed ID: 32671412
[TBL] [Abstract][Full Text] [Related]
8. High-level expression of ARID1A predicts a favourable outcome in triple-negative breast cancer patients receiving paclitaxel-based chemotherapy.
Lin YF; Tseng IJ; Kuo CJ; Lin HY; Chiu IJ; Chiu HW
J Cell Mol Med; 2018 Apr; 22(4):2458-2468. PubMed ID: 29392887
[TBL] [Abstract][Full Text] [Related]
9. [Effect of miR-342-3p on chemotherapy sensitivity in triple-negative breast cancer].
Ma T; Zhang J; Wu J; Tang J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2014 May; 39(5):488-95. PubMed ID: 24921394
[TBL] [Abstract][Full Text] [Related]
10. Truncated HDAC9 identified by integrated genome-wide screen as the key modulator for paclitaxel resistance in triple-negative breast cancer.
Lian B; Pei YC; Jiang YZ; Xue MZ; Li DQ; Li XG; Zheng YZ; Liu XY; Qiao F; Sun WL; Ling H; He M; Yao L; Hu X; Shao ZM
Theranostics; 2020; 10(24):11092-11109. PubMed ID: 33042272
[No Abstract] [Full Text] [Related]
11. Enhanced cytotoxic activity of doxorubicin through the inhibition of autophagy in triple negative breast cancer cell line.
Aydinlik S; Erkisa M; Cevatemre B; Sarimahmut M; Dere E; Ari F; Ulukaya E
Biochim Biophys Acta Gen Subj; 2017 Feb; 1861(2):49-57. PubMed ID: 27842219
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cells.
Tanei T; Choi DS; Rodriguez AA; Liang DH; Dobrolecki L; Ghosh M; Landis MD; Chang JC
Breast Cancer Res; 2016 Jan; 18(1):6. PubMed ID: 26757880
[TBL] [Abstract][Full Text] [Related]
13. USP18 reduces paclitaxol sensitivity of triple-negative breast cancer via autophagy.
Ge X; Zhang D; Song S; Mi Y; Shen Y; Jiang Q; Liang Y; Wang J; Ye Q
Biochem Biophys Res Commun; 2022 Apr; 599():120-126. PubMed ID: 35180471
[TBL] [Abstract][Full Text] [Related]
14. Knockdown of lncRNA H19 restores chemo-sensitivity in paclitaxel-resistant triple-negative breast cancer through triggering apoptosis and regulating Akt signaling pathway.
Han J; Han B; Wu X; Hao J; Dong X; Shen Q; Pang H
Toxicol Appl Pharmacol; 2018 Nov; 359():55-61. PubMed ID: 30244121
[TBL] [Abstract][Full Text] [Related]
15. LIN9 confers paclitaxel resistance in triple negative breast cancer cells by upregulating CCSAP.
Lai H; Wang R; Li S; Shi Q; Cai Z; Li Y; Liu Y
Sci China Life Sci; 2020 Mar; 63(3):419-428. PubMed ID: 31420851
[TBL] [Abstract][Full Text] [Related]
16. Codelivery of anti-cancer agents via double-walled polymeric microparticles/injectable hydrogel: A promising approach for treatment of triple negative breast cancer.
Davoodi P; Ng WC; Srinivasan MP; Wang CH
Biotechnol Bioeng; 2017 Dec; 114(12):2931-2946. PubMed ID: 28832946
[TBL] [Abstract][Full Text] [Related]
17. Expression of miR-335 in triple-negative breast cancer and its effect on chemosensitivity.
Hao J; Lai M; Liu C
J BUON; 2019; 24(4):1526-1531. PubMed ID: 31646803
[TBL] [Abstract][Full Text] [Related]
18. Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.
Kim EM; Mueller K; Gartner E; Boerner J
J Surg Res; 2013 Nov; 185(1):231-9. PubMed ID: 23899511
[TBL] [Abstract][Full Text] [Related]
19. CCAAT enhancer binding protein delta activates vesicle associated membrane protein 3 transcription to enhance chemoresistance and extracellular PD-L1 expression in triple-negative breast cancer.
Zhao Y; Yu Y; Li X; Guo A
J Exp Clin Cancer Res; 2024 Apr; 43(1):115. PubMed ID: 38627816
[TBL] [Abstract][Full Text] [Related]
20. Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer.
Skor MN; Wonder EL; Kocherginsky M; Goyal A; Hall BA; Cai Y; Conzen SD
Clin Cancer Res; 2013 Nov; 19(22):6163-72. PubMed ID: 24016618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
